Monday December 01 2008 | Biotechnology feed | All feeds
|
|
Monday December 01 2008 | Biotechnology feed | All feeds
|
|
|
CTM Biotech - Appointment of Malcolm Brattle as Non-Executive Director Cambridge,
UK, 25th August 2004. CTM
BioTech Ltd, the provider of process development services to the bio-pharma
industry, today announces the appointment of Malcolm Brattle as Non-Executive
Director. Malcolm has
a wealth of experience in the successful provision of bio-pharmacuetical
services. His previous position was that of Sales and Marketing Director for
Q-One Biotech, a biologicals safety testing company he co-founded some 14 years
ago. Prior its sale to BioReliance, Q-One employed approx. 250 employees based
in the UK and the US. David Gough,
Chairman of CTM, commented ‘I am delighted to welcome Malcolm to the team at
CTM BioTech. His previous experience in, and knowledge of, the sector will prove
valuable to the company as we look to develop into a leader in the field of bio-pharma
process development. That someone
with Malcolm’s experience should wish to join CTM is a fantastic validation of
our positioning and potential’ Essentially
CTM is looking to bridge the gap between what bio-pharma companies are able to
do in-house and what CMOs can do by way of the production of clinical trial
material. The company
specialises in the upstream and downstream development of GMP compliant
procedures and in the manufacture of small quantities of non-GMP product derived
from eukaryotic and prokaryotic client cell lines. CTM also
offer consultancy services to advise organisations as to how best develop their
products in a GMP-compliant way and project management services to help client
companies in their selection and management of appropriately qualified and
experienced CMOs. In addition to bank and private investment funding, CTM Biotech has also benefited from the support of Babraham Bioscience Technologies (BBT) Ltd’s BioConcepts programme. BioConcepts is partly funded by the East of England Development Agency as a regional Enterprise Hub. Contact: Jon Mowles,
Commercial Director E-mail:
jon.mowles@ctmbiotech.co.uk Phone :
07710 281 293 Web :
www.ctmbiotech.co.uk CTM
BioTech Babraham
Research Campus Babraham Cambridge
CB2 4AT, UK Notes
for Editors Protein-based
pharmaceuticals are one of the success stories of recent years and continue to
grow in importance. In 2002,
approximately one third of all new approvals by the FDA were biologics -
monoclonal antibodies, therapeutic proteins or vaccines.
Several biologics, including erythropoeitin, interferon gamma and
rituximab, have reached ‘blockbuster’ status.
Funding In
addition to bank and private investment funding, CTM Biotech has also benefited
from the support of Babraham Bioscience Technologies (BBT) Ltd’s BioConcepts
programme. BioConcepts is partly
funded by the East of England Development Agency as a regional Enterprise Hub.
Babraham
BioConcepts
Babraham
Bioscience Technologies (BBT) Ltd has built on the success of its current
bioincubator by developing Babraham
BioConcepts, an
holistic support facility to help innovators and aid CTM
Biotech’s Services
Amongst the
key services offered are batch production for lead candidate clones, process
development to optimise protein expression during fermentation, batch
purification and purification process development to complement the upstream
process. Other services include
cell line manufacture, clone selection and isolation, definition of process
operating parameters and “edges of failure”, the generation of Manufacturing
Directions and technology transfer expertise, to full GMP production where
required. CTM offers
expertise in bacterial, mammalian, yeast and baculovirus protein expression
systems, enhanced by an array of upstream and downstream capabilities. These
range from small-scale shake flask and spinner bottles for clone evaluation, to
fermentors (up to 125L), hollow fibre systems and roller bottle apparatus. All
work is conducted to fully documented systems. Malcolm Brattle, BScMalcolm has
worked in the biopharmaceutical industry for over 30 years. In 1990 he was
one of the founders of Q-One Biotech, a company providing biosafety testing,
validation and GMP manufacturing services to biopharma companies worldwide.
Malcolm was responsible for successfully developing the business in Europe, USA
and Asia Pacific. Q-One became the market leader in Europe and Asia and opened a
US subsidiary in Worcester, MA. In September 2003 Q-One was sold to
BioReliance. The Non-Executive Director role at CTM is Malcolm's first
appointment since he left BioReliance. Jon Mowles, BSc, MSc, Commercial DirectorAfter
completing his Masters degree at the Royal Post Graduate Medical School, London,
Jon worked as a microbiologist at University College Hospital, London. He was
one of the founding members of staff to establish the European Collection of
Animal Cell Cultures (ECACC), Porton Down, Salisbury, and as Deputy Head, was
responsible for all commercial aspects of the Collection. Jon then joined the
Canadian company BioChem Pharma as Monoclonal Antibody Production Manager
(responsible for both in-house and contract production), and ultimately became
General Manager of the UK subsidiary. Prior
to co-founding CTM BioTech, Jon worked in both the UK and Europe as an
independent consultant, on contracts ranging from sourcing and managing
prokaryotic production for the pharmaceutical industry, to contract monoclonal
antibody production for diagnostic use. He also had a significant role in the
planning and development of a new GMP bio-pharmaceutical contract production
facility in France. Projects were
completed for a variety of companies from European SME’s to global Japanese
corporations.
|
|
|
